Brands like Kourtney Kardashian's Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...

Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

The company believes these combinations create a broader approach to treating neurodegenerative diseases ・Preclinical studies have demonstrated these combinations significant ...

More than 1.6 million Britons are set to get the ‘King Kong’ of fat jabs on the NHS over the next 12 years. Mounjaro – which ...

In a consultation the UK's drugs watchdog has now proposed the NHS expands its use for weight loss for those who are severely ...

More than 1.6 million Britons are set to get the ‘King Kong’ of fat jabs on the NHS over the next 12 years. Mounjaro – which ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

"A malfunctioning fire sprinkler device has never caused a fire”, said Shane Ray, President of the National Fire Sprinkler ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...